Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.57
+0.09 (1.06%)
At close: Apr 2, 2026, 4:00 PM EDT
8.51
-0.06 (-0.70%)
After-hours: Apr 2, 2026, 4:10 PM EDT
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 28, which predicts a 226.72% increase from the current stock price of 8.57.
Price Target: $28 (+226.72%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $28 | Buy | Initiates | $28 | +226.72% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $84 → $56 | Buy | Maintains | $84 → $56 | +553.44% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,043.52% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,043.52% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $280 → $140 | Buy | Maintains | $280 → $140 | +1,533.61% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
82.57M
from 43.77M
Increased by 88.66%
Revenue Next Year
13.17M
from 82.57M
Decreased by -84.05%
EPS This Year
-2.55
from -4.19
EPS Next Year
-6.79
from -2.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 85.8M | 13.7M | |||
| Avg | 82.6M | 13.2M | |||
| Low | 80.1M | 12.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 96.1% | -83.4% | |||
| Avg | 88.7% | -84.0% | |||
| Low | 83.1% | -84.5% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -2.65 | -7.06 |
| Avg | -2.55 | -6.79 |
| Low | -2.47 | -6.59 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.